Deal Announcement: Corbett Keeling advised SONEAS and its shareholders on its sale to UQUIFA

Corbett Keeling has advised SONEAS and its shareholders on its sale to UQUIFA, the Vivimed Group's API business. Soneas broadens Uquifa's offering in the CDMO sector with new development capabilities and an enhance project pipeline.

About Soneas Soneas, established in 1996, with a team strength of 144 people, is a Budapest headquartered firm with business verticals focused on research, development, and custom manufacturing, targeted at the innovator pharma and fine chemical sectors.

About Uquifa Uquifa has three FDA inspected manufacturing sites across Spain and Mexico and caters to the generic and ethical API segments of the global pharma market. It has had a trusted franchise across regulated markets for 80 years.